You are here

Development of a Recombinant Vaccine Against Streptococcus Pyogenes Infection and Disease

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-12-C-0183
Agency Tracking Number: A12A-027-0056
Amount: $100,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: A12a-T027
Solicitation Number: 2012.A
Solicitation Year: 2012
Award Year: 2012
Award Start Date (Proposal Award Date): 2012-09-12
Award End Date (Contract End Date): N/A
Small Business Information
2213 Evening Sun RD
Nazareth, PA 18064-
United States
DUNS: 962757584
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Garry Morefield
 (610) 573-9620
Business Contact
 Garry Morefield
Title: President
Phone: (610) 573-9620
Research Institution
 Purdue University
 Harm Hogenesch
625 Harrison ST
West Lafayette, IN 47907-
United States

 (765) 496-2026
 Nonprofit College or University

In this phase I proposal we propose development studies for a vaccine targeting diseases caused by infection with Streptococcus pyogenes. This vaccine utilizes a recombinant fusion protein comprising of SpeA, a secreted toxin, and SpeB, a surface bound and secreted cysteine protease. Combination of these two virulence factors provides protection against most strains of the bacteria. This antigen has demonstrated promise in proof of concept potency studies in which mice were protected from toxic shock as well as infection following challenge. The overall goal is to produce a lead formulation for the SpeAB vaccine, optimized for safety, potency, and stability, which can be rapidly advanced through non-clinical safety studies and into phase I clinical trials. To achieve this goal we utilize a rational, systematic approach to formulation development allowing rapid identification of a robust formulation. The biophysical characteristics of SpeAB and how environmental factors such as pH, ionic strength, and temperature impact the antigen will be determined. Interactions with aluminum adjuvant systems will also be investigated to develop a robust vaccine formulation. Successful commercialization of this vaccine will reduce morbidity and mortality rates, as well as medical care costs, associated with S.pyogenes infection in both military and civilian populations.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government